PE20090192A1 - Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo - Google Patents

Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo

Info

Publication number
PE20090192A1
PE20090192A1 PE2007001013A PE2007001013A PE20090192A1 PE 20090192 A1 PE20090192 A1 PE 20090192A1 PE 2007001013 A PE2007001013 A PE 2007001013A PE 2007001013 A PE2007001013 A PE 2007001013A PE 20090192 A1 PE20090192 A1 PE 20090192A1
Authority
PE
Peru
Prior art keywords
salt
morpholin
indol
pyridin
hydroxy
Prior art date
Application number
PE2007001013A
Other languages
English (en)
Inventor
Anna Lena Berg
Ratan Bhat
Tesfai Sebhatu
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090192A1 publication Critical patent/PE20090192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA A UNA SAL CITRATO DE 2-HIDROXI-3-[5-(MORFOLIN-4-ILMETIL)PIRIDIN-2-IL]1H-INDOL-5-CARBONITRILO, UNA FORMA A CRISTALINA DE LA MISMA QUE PRESENTA VALORES d DE DIFRACCION DE RAYOS X EN POLVO E INTENSIDAD RELATIVA DE 12,7(vs), 6,8(vs), 6,3(s), 4,38(s), 4,23(s) Y 3,41(m) Å. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACIONDE DICHA SAL QUE COMPRENDE HACER REACCIONAR 2-HIDROXI-3-[5-(MORFOLIN-4-ILMETIL)PIRIDIN-2-IL]1H-INDOL-5-CARBONITRILO CON ACIDO CITRICO EN UN SOLVENTE TAL COMO UNA MEZCLA DE ETANOL Y AGUA O ACIDO ACETICO. DICHA SAL ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS ASOCIADOS A LA GLUCOGENO SINTASA QUINASA-3 TALES COMO DETERIORO DE LA MEMORIA ASOCIADO A LA EDAD, DETERIORO COGNITIVO SIN DEMENCIA, DETERIORO COGNITIVO LEVE, ENTRE OTROS
PE2007001013A 2006-02-02 2007-08-02 Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo PE20090192A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
PCT/SE2007/000086 WO2007089191A1 (en) 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use

Publications (1)

Publication Number Publication Date
PE20090192A1 true PE20090192A1 (es) 2009-03-20

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001013A PE20090192A1 (es) 2006-02-02 2007-08-02 Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo

Country Status (24)

Country Link
US (2) US8008294B2 (es)
EP (1) EP1981869A4 (es)
JP (1) JP2009525324A (es)
KR (1) KR20080098022A (es)
CN (2) CN101378754A (es)
AR (1) AR059225A1 (es)
AU (1) AU2007210336B2 (es)
BR (1) BRPI0706745A2 (es)
CA (1) CA2641900A1 (es)
EC (1) ECSP088647A (es)
IL (1) IL192888A0 (es)
MX (1) MX2008009719A (es)
MY (1) MY146102A (es)
NO (1) NO20083784L (es)
NZ (1) NZ570849A (es)
PE (1) PE20090192A1 (es)
RU (1) RU2415137C2 (es)
SA (1) SA07280004B1 (es)
SG (1) SG169381A1 (es)
TW (1) TW200800977A (es)
UA (1) UA94251C2 (es)
UY (1) UY30126A1 (es)
WO (1) WO2007089191A1 (es)
ZA (1) ZA200806725B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
RU2009138136A (ru) * 2007-04-18 2011-05-27 Астразенека Аб (Se) Новый способ получения соединения 2-гидрокси-3-[5-(морфолин-4-илметил)пиридин-2-ил]1н-индол-5-карбонитрила 701
JP2010535200A (ja) * 2007-07-30 2010-11-18 アストラゼネカ・アクチエボラーグ ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373263B1 (en) 2001-04-05 2004-10-27 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
US20070203137A1 (en) 2007-08-30
KR20080098022A (ko) 2008-11-06
ZA200806725B (en) 2009-07-29
US8008294B2 (en) 2011-08-30
IL192888A0 (en) 2009-02-11
BRPI0706745A2 (pt) 2011-04-05
WO2007089191A1 (en) 2007-08-09
RU2415137C2 (ru) 2011-03-27
NZ570849A (en) 2011-01-28
UA94251C2 (ru) 2011-04-26
JP2009525324A (ja) 2009-07-09
CN101379053A (zh) 2009-03-04
SA07280004B1 (ar) 2011-10-29
UY30126A1 (es) 2007-09-28
CA2641900A1 (en) 2007-08-09
EP1981869A1 (en) 2008-10-22
EP1981869A4 (en) 2010-08-25
SG169381A1 (en) 2011-03-30
MX2008009719A (es) 2008-09-04
CN101378754A (zh) 2009-03-04
NO20083784L (no) 2008-10-13
AU2007210336A1 (en) 2007-08-09
US20090023732A1 (en) 2009-01-22
AR059225A1 (es) 2008-03-19
AU2007210336B2 (en) 2011-03-24
MY146102A (en) 2012-06-29
RU2008131906A (ru) 2010-03-10
TW200800977A (en) 2008-01-01
ECSP088647A (es) 2008-08-29

Similar Documents

Publication Publication Date Title
TW200626068A (en) Active compounds for seed treatment
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
WO2007070504A3 (en) Stable and palatable oral liquid sumatriptan compositions
PE20090192A1 (es) Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
RS51954B (en) CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN
PE20100267A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
WO2007076245A3 (en) Novel hydrogen sulfate salt
MX2009005413A (es) Formas cristalinas del acido zoledronico.
EA201101669A1 (ru) Новая соль базедоксифена
MY151295A (en) Pyrimidyl indoline compound
MX346525B (es) Proceso para preparar y purificar n-benzoil-estaurosporina.
ECSP055859A (es) Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
WO2003070731A3 (en) Azabicyclic compounds for the treatment of disease
TW200420541A (en) Crystalline forms
BRPI0708291B8 (pt) forma cristalina beta de sal de arginina de perindopril, processo para sua preparação, composições farmacêuticas que a contêm e seus usos
PE20030923A1 (es) Forma polimorfica cristalina de clorhidrato de irinotecan
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
BR112016011632A2 (pt) Método para sintetizar um derivado de porfirina, método para sintetizar um composto, método para sintetizar um composto hidrato, método de síntese, recipiente compreendendo uma pluralidade de compostos, formulação farmacêutica, método para purificar um composto, cristal, e, forma cristalina de complexo [5,10,15,20-tetrakis(1,3-dietilimidazólio-2-il)porfirinato]manganês(iii) cloreto hidrato
GEP20125680B (en) Carbonic and sulphuric acid salts of 3-(2,2,2-trimethylhydra-zinium) ropionate esters and their use for 3-(2,2,2-rimethyl- hydrazinium) propionate dihydrate preparation
TW200800993A (en) Organic compounds
TW200715961A (en) Herbicide composition
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
WO2007032009A3 (en) Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed